2256 — Abbisko Medicine Share News
0.000.00%
Last trade - 00:00- HK$4.55bn
- HK$2.21bn
- CNY612.12m
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly
Brief: Abbisko Cayman To Place 42.9 Million Shares
Brief: Abbisko Cayman Says Irpagratinib Granted Orphan Drug Designation By EMA For Hepatocellular Carcinoma
Brief: Abbisko Cayman Says FDA Clears IND Application For ABSK061 For Achondroplasia In Children
Brief: Abbisko Cayman Says FDA Grants Orphan Drug Designation To Abbisko's Absk061 For Achondroplasia
Brief: Abbisko Cayman Says US FDA Grants Rare Pediatric Disease Designation For FGFR2/3 Inhibitor ABSK061
Brief: Abbisko Cayman Says CEO Purchased Total 45,000 Shares Of Co At Average Price HK$11.26 Per Share
Brief: Abbisko Cayman Says FDA Grants Fast Track Designation To Abbisko's Irpagratinib
Brief: Abbisko Cayman's New Drug Application For Pimicotinib Formally Accepted By U.S. FDA
Brief: Abbisko Cayman Says NMPA Clears IND Application For Unit's Abbisko's Absk141
Brief: Abbisko Cayman Says Abbisko Therapeutics' CSF-1R Inhibitor Pimicotinib Approved By China NMPA